"Syngene – दवा अनुसंधान, विकास और उत्पादन में आपकी दुनिया का भरोसेमंद वैज्ञानिक साथी।"

Technical Chart Analysis

Syngene’s stock is currently showing a moderately bullish trend. The price is trading above its key moving averages, including the 20-day and 50-day exponential moving averages (EMA), signaling short- to medium-term strength. The Relative Strength Index (RSI) is around 60, indicating healthy buying momentum without being overbought. MACD (Moving Average Convergence Divergence) is positive, supporting bullish momentum. The stock has strong support near ₹650 and faces resistance around ₹685–₹700. Volume trends show consistent participation, confirming buyer interest. Given this technical setup, Syngene looks poised for a gradual uptrend, with cautious monitoring near resistance zones. Recent News & Upcoming Event Syngene’s management will hold an analyst call to discuss Q2 FY26 results. Participation in upcoming international pharma conferences (e.g., CPHI India in November 2025). Announced strategic focus on biologics, peptide APIs, and novel drug delivery systems. Market analysts suggest cautious optimism due to recent margin contraction but emphasize long-term growth potential. Positive Points Leadership position in Indian CRAMS with global clientele. Diversification into biologics and specialty peptides increasing growth visibility. Strong cash flows, low debt, and healthy balance sheet. Ongoing innovation and investment into newer service platforms. Negative Points Recent margin contraction impacting short-term profitability. Moderate revenue growth amid inventory corrections. High valuation may limit near-term upside without earnings acceleration. Dependency on global pharma industry cyclicality and contract renewals.